Literature DB >> 31135997

Trends in Prescribed Central Nervous System Depressant Medications Among Adults Who Regularly Consume Alcohol: United States 1999 to 2014.

Jacob T Borodovsky1, Melissa J Krauss1, Tingying Chi1, Laura J Bierut1, Richard A Grucza1.   

Abstract

BACKGROUND: Although the risks of using central nervous system depressant (CNS-D) medications with alcohol are well documented, little is known about trends in prescribed use of these medications among individuals who regularly consume alcohol (i.e., trends in "concurrent use"). We examined changes in the prevalence of prescribed CNS-D medications among individuals who drank alcohol on 52 or more occasions in the past year ("regular drinking"). CNS-D medications included sedative-hypnotics (subclassified as anxiolytics or sleep medications) and opioids.
METHODS: We used 8 cross-sectional cycles of the National Health and Nutrition Examination Survey (1999-2000 to 2013-2014) from participants aged 20 and older (n = 37,709). We used log-binomial regression to examine (i) prevalence trends of prescribed CNS-D medication use, (ii) trend differences by drinking status, and (iii) correlates of CNS-D medication use.
RESULTS: Among those who drink regularly, the relative annual increase in prevalence of sedative-hypnotic use was 5.3% (95% CI: 2.7 to 7.9): Anxiolytic and sleep medication use increased annually by 3.7% (95% CI: 0.8 to 6.7) and 11.2% (95% CI: 6.5 to 16.0), respectively. Opioid use trends among those who drink regularly were not statistically significant but were nonlinear. Differences in CNS-D medication trends between those who drink regularly and those who drink infrequently/abstain were not statistically significant. Those who drink regularly were less likely than those who drink infrequently/abstain to use opioids (adjusted relative risk [ARR]: 0.69, 95% CI: 0.60 to 0.78) and anxiolytics (ARR: 0.71, 95% CI: 0.61 to 0.81), but not sleep medications (ARR: 1.04, 95% CI: 0.80 to 1.35). Those aged 40 and older were 2 to 5 times as likely as those aged 20 to 29 to use sedative-hypnotics.
CONCLUSIONS: Among those who drink regularly, the prevalence of prescribed sedative-hypnotic use increased and prescribed opioid use remained common. These trends indicate that a substantial portion of the population is at risk of alcohol-related adverse drug reactions-particularly those aged 40 and older.
© 2019 by the Research Society on Alcoholism.

Entities:  

Keywords:  Alcohol; Benzodiazepine; Opioid; Sleep Medication; Trends

Year:  2019        PMID: 31135997      PMCID: PMC6602821          DOI: 10.1111/acer.14081

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  31 in total

1.  Permutation tests for joinpoint regression with applications to cancer rates.

Authors:  H J Kim; M P Fay; E J Feuer; D N Midthune
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

2.  Age and gender trends in long-term opioid analgesic use for noncancer pain.

Authors:  Cynthia I Campbell; Constance Weisner; Linda Leresche; G Thomas Ray; Kathleen Saunders; Mark D Sullivan; Caleb J Banta-Green; Joseph O Merrill; Michael J Silverberg; Denise Boudreau; Derek D Satre; Michael Von Korff
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

Review 3.  Mechanisms of fatal opioid overdose.

Authors:  J M White; R J Irvine
Journal:  Addiction       Date:  1999-07       Impact factor: 6.526

Review 4.  Risks of combined alcohol/medication use in older adults.

Authors:  Alison A Moore; Elizabeth J Whiteman; Katherine T Ward
Journal:  Am J Geriatr Pharmacother       Date:  2007-03

5.  Prevalence and characteristics of opioid use in the US adult population.

Authors:  Judith Parsells Kelly; Suzanne F Cook; David W Kaufman; Theresa Anderson; Lynn Rosenberg; Allen A Mitchell
Journal:  Pain       Date:  2008-03-14       Impact factor: 6.961

6.  Characterization of the interaction of zopiclone with gamma-aminobutyric acid type A receptors.

Authors:  M Davies; J G Newell; J M Derry; I L Martin; S M Dunn
Journal:  Mol Pharmacol       Date:  2000-10       Impact factor: 4.436

7.  The medicalization of sleeplessness: a public health concern.

Authors:  Mairead Eastin Moloney; Thomas R Konrad; Catherine R Zimmer
Journal:  Am J Public Health       Date:  2011-06-16       Impact factor: 9.308

8.  GPs' attitudes to benzodiazepine and 'Z-drug' prescribing: a barrier to implementation of evidence and guidance on hypnotics.

Authors:  A Niroshan Siriwardena; Zubair Qureshi; Steve Gibson; Sarah Collier; Martin Latham
Journal:  Br J Gen Pract       Date:  2006-12       Impact factor: 5.386

Review 9.  Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

Authors:  Leah M Hesse; Lisa L von Moltke; David J Greenblatt
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  Alcohol and medication interactions.

Authors:  R Weathermon; D W Crabb
Journal:  Alcohol Res Health       Date:  1999
View more
  2 in total

1.  The changing landscape of alcohol use disorder and problem drinking in the USA: implications for primary care.

Authors:  Richard A Grucza; Jennifer K Bello-Kottenstette; Carrie M Mintz; Jacob T Borodovsky
Journal:  Fam Pract       Date:  2020-11-28       Impact factor: 2.267

2.  Association Between Benzodiazepine Use With or Without Opioid Use and All-Cause Mortality in the United States, 1999-2015.

Authors:  Kevin Y Xu; Sarah M Hartz; Jacob T Borodovsky; Laura J Bierut; Richard A Grucza
Journal:  JAMA Netw Open       Date:  2020-12-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.